Markets:

Overview

News

Currencies

International

Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

3.108 -0.242 (-7.22%)

Streaming Delayed Price Updated: 10:56 AM EDT, Apr 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about bioAffinity Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

April 07, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

April 01, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

March 25, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

March 17, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

March 13, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

March 10, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

March 03, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

February 25, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

February 19, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study

February 17, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

February 09, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

January 07, 2026

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

December 03, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

November 14, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

November 05, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

October 28, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

October 20, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

October 16, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

October 15, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

October 09, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

October 08, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

October 07, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

September 30, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

September 29, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

MAGA Stocks Undercard: SNYR GUTS MRM MYSE Under $3 To Watch Now….more inside

September 26, 2025

Via AB Newswire

Topics Economy

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

September 26, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

September 17, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

September 09, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA

September 03, 2025

From bioAffinity Technologies

Via Business Wire

bioAffinity Technologies Appoints New Members to Board of Directors

August 18, 2025

From bioAffinity Technologies, Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.